Pregnancy outcome following maternal exposure to mirtazapine

Journal of Clinical Psychopharmacology

Volumn 35, Issue 3, 2015, Pages 250-259

  Winterfeld, Ursula ^a   Klinger, Gil ^b   Panchaud, Alice ^a,c   Stephens, Sally ^d   Arnon, Judy ^e   Malm, Heli ^f   Te Winkel, Bernke ^g   Clementi, Maurizio ^h   Pistelli, Alessandra ⁱ   Maňáková, Eva ^j   Eleftheriou, Georgios ^k   Merlob, Paul ^b   Kaplan, Yusuf C ^l   Buclin, Thierry ^a   Rothuizen, Laura E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d Regional Drug Therapeutics Centre   (United Kingdom)

^e MINISTRY OF HEALTH   (Israel)

^f UNIVERSITY OF HELSINKI   (Finland)

^g Netherlands Pharmacovigilance Centre Lareb   (Netherlands)

^h Servizio di Informazione Teratologica   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j CHARLES UNIVERSITY   (Czech Republic)

^k Poison Control Center   (Italy)

^l IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

more..

Author keywords

Antidepressant; birth defect; mirtazapine; pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID; VENLAFAXINE; MIANSERIN;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHROMOSOME DISORDER; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; EATING DISORDER; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC DISORDER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION; STATISTICAL SIGNIFICANCE; TREND STUDY; ABNORMALITIES, DRUG-INDUCED; ANALOGS AND DERIVATIVES; BIRTH WEIGHT; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; DEPRESSIVE DISORDER; DRUG EFFECTS; GESTATIONAL AGE; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOLOGY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS; BIRTH WEIGHT; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; GESTATIONAL AGE; HUMANS; MIANSERIN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 84929161627     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000309     Document Type: Article

References (37)

1. Bennett HA, Einarson A, Taddio A, Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004; 103: 698-709.
2. Bosquet M, Egeland B,. Associations among maternal depressive symptomatology, state of mind and parent and child behaviors: implications for attachment-based interventions. Attach Hum Dev. 2001; 3: 173-199.
3. Grigoriadis S, VonderPorten EH, Mamisashvili L, The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013; 74: e321-e341.
4. Henrichs J, Schenk JJ, Roza SJ, Maternal psychological distress and fetal growth trajectories: the Generation R Study. Psychol Med. 2010; 40: 633-643.
5. Dayan J, Creveuil C, Marks MN, Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med. 2006; 68: 938-946.
6. di Scalea TL, Wisner KL,. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2009; 10: 2593-2607.
7. Fournier JC, DeRubeis RJ, Hollon SD, Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303: 47-53.
8. Bennett IM, Marcus SC, Palmer SC, Pregnancy-related discontinuation of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv. 2010; 61: 386-391.
9. Meijer WE, Heerdink ER, Leufkens HG, Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol. 2004; 60: 57-61.
10. Watanabe N, Omori IM, Nakagawa A, Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;(7): CD006528.
11. Croom KF, Perry CM, Plosker GL,. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009; 23: 427-452.
12. Kesim M, Yaris F, Kadioglu M, Mirtazapine use in two pregnant women: is it safe? Teratology. 2002; 66: 204.
13. Rohde A, Dembinski J, Dorn C,. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet. 2003; 268: 219-221.
14. Yaris F, Kadioglu M, Kesim M, Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol. 2004; 19: 235-238.
15. Uguz F,. Low-dose mirtazapine added to selective serotonin reuptake inhibitors in pregnant women with major depression or panic disorder including symptoms of severe nausea, insomnia and decreased appetite: three cases. J Matern Fetal Neonatal Med. 2013; 26: 1066-1068.
16. Guclu S, Gol M, Dogan E, Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet. 2005; 272: 298-300.
17. Saks B,. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases. Arch Womens Ment Health. 2001; 3: 165-170.
18. Uguz F,. Low-dose mirtazapine in treatment of major depression developed following severe nausea and vomiting during pregnancy: two cases. Gen Hosp Psychiatry. 2014; 36: 125.e5-125.e6.
19. Biswas PN, Wilton LV, Shakir SA,. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol. 2003; 17: 121-126.
20. Lennestal R, Kallen B,. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007; 27: 607-613.
21. Reis M, Kallen B,. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40: 1723-1733.
22. Djulus J, Koren G, Einarson TR, Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry. 2006; 67: 1280-1284.
23. Einarson A, Choi J, Einarson TR, Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009; 54: 242-246.
24. Schaefer C, Ornoy A, Clementi M, Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol. 2008; 26: 36-41.
25. Winterfeld U, Allignol A, Panchaud A, Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG. 2013; 120: 463-471.
26. Sokolover N, Merlob P, Klinger G,. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. Can J Clin Pharmacol. 2008; 15: e188-e190.
27. Ellfolk M, Malm H,. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol. 2010; 30: 249-260.
28. Malm H,. Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome. Ther Drug Monit. 2012; 34: 607-614.
29. Huybrechts KF, Palmsten K, Avorn J, Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014; 370: 2397-2407.
30. Oberlander TF, Warburton W, Misri S, Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008; 83: 68-76.
31. Merlob P, Birk E, Sirota L, Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol. 2009; 85: 837-841.
32. Pedersen LH, Henriksen TB, Vestergaard M, Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009; 339: b3569.
33. Malm H, Artama M, Gissler M, Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011; 118: 111-120.
34. Hansen D, Lou HC, Olsen J,. Serious life events and congenital malformations: a national study with complete follow-up. Lancet. 2000; 356: 875-880.
35. Andersson L, Sundstrom-Poromaa I, Wulff M, Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am J Epidemiol. 2004; 159: 872-881.
36. Kjaersgaard MI, Parner ET, Vestergaard M, Prenatal antidepressant exposure and risk of spontaneous abortion- A population-based study. PLoS One. 2013; 28: e72095.
37. Ross LE, Grigoriadis S, Mamisashvili L, Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013; 70: 436-443.